Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.
Read the notice.
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has